E. Ohman J or Asset Management AB Sells 34,459 Shares of Boston Scientific Co. (NYSE:BSX)

E. Ohman J or Asset Management AB lowered its position in Boston Scientific Co. (NYSE:BSX) by 5.0% in the third quarter, HoldingsChannel.com reports. The fund owned 660,385 shares of the medical equipment provider’s stock after selling 34,459 shares during the quarter. Boston Scientific accounts for approximately 1.4% of E. Ohman J or Asset Management AB’s portfolio, making the stock its 17th biggest holding. E. Ohman J or Asset Management AB’s holdings in Boston Scientific were worth $55,340,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC lifted its stake in Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares during the last quarter. First Foundation Advisors acquired a new stake in Boston Scientific in the first quarter valued at $25,000. Triad Wealth Partners LLC acquired a new stake in Boston Scientific in the second quarter valued at $26,000. Values First Advisors Inc. acquired a new stake in Boston Scientific in the third quarter valued at $28,000. Finally, Andra AP fonden acquired a new stake in Boston Scientific in the second quarter valued at $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the sale, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company’s stock, valued at approximately $13,639,695. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 316,253 shares of company stock worth $26,714,298 in the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $85.11 on Friday. Boston Scientific Co. has a fifty-two week low of $49.15 and a fifty-two week high of $88.79. The stock has a market cap of $124.86 billion, a PE ratio of 71.52, a PEG ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm’s fifty day moving average price is $83.19 and its two-hundred day moving average price is $77.57.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the prior year, the firm earned $0.50 EPS. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, equities analysts expect that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. TD Cowen raised their target price on shares of Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday. BTIG Research raised their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Morgan Stanley raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Royal Bank of Canada raised their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.